BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/19/2015 5:28:00 PM | Browse: 1255 | Download: 1292
 |
Received |
|
2014-10-29 08:44 |
|
Peer-Review Started |
|
2014-11-01 11:42 |
|
To Make the First Decision |
|
2014-12-12 17:27 |
|
Return for Revision |
|
2014-12-16 13:16 |
|
Revised |
|
2014-12-27 22:33 |
|
Second Decision |
|
2015-01-21 20:58 |
|
Accepted by Journal Editor-in-Chief |
|
2015-01-23 18:15 |
|
Accepted by Executive Editor-in-Chief |
|
2015-02-02 20:16 |
|
Articles in Press |
|
2015-02-02 20:16 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-04-28 14:13 |
|
Publish the Manuscript Online |
|
2015-05-19 17:28 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi and Andrea Lorenzo Inghilesi |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Protocollo TESORM by Regione Toscana |
|
| Università degli Studi di Firenze |
|
| Bayer Health Care s.p.a |
|
|
| Corresponding Author |
Stefano Colagrande, MD, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Università degli Studi di Firenze-Azienda Ospedaliero-Universitaria Careggi, Radiodiagnostica 2, Largo Brambilla 3, 50134 Florence,
Italy. stefano.colagrande@unifi.it
|
| Key Words |
Modified Response Evaluation Criteria in Solid Tumors; Diffusion weighted imaging; Barcelona clinic liver cancer; Advanced hepatocellular carcinoma; Sorafenib; Advanced hepatocellular carcinoma second line therapies; Perfusion weighted imaging; Response evaluation; Hepatocellular carcinoma follow-up; Response Evaluation Criteria in Solid Tumors |
| Core Tip |
Advanced stage hepatocellular carcinoma comprehends a wide range of patients with different general conditions. The main therapeutic option is represented by sorafenib. Although the treatment has shown a significant increase in mean overall survival, only a part of patients actually shows benefits. Differentiating responder from non-responder patients is a pivotal challenge for the future. In particular, finding parameters quantitatively describing perfusion grade, and then able to predict the sensitivity of the lesions to anti-angiogenic agents could help stratifying patients in terms of responsiveness before the beginning of the therapy itself. This would bring a great help in management of these patients.
|
| Publish Date |
2015-05-19 17:28 |
| Citation |
Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 |
| URL |
http://www.wjgnet.com/1948-5182/full/v7/i8/1041.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v7.i8.1041 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
